{"slug":"kpv","verification":{"valid":true,"entries":37,"head":"58d57c68b8fe4cde1c3cb0c11d3d6bfa647f7e911cc9e67213c6aa2614248159"},"energy":{"passes":37,"tokens_in":3103,"tokens_out":376,"tokens_total":3479,"cost_usd":0,"models":{"grok/grok-4.3":1,"grok-4.3":19,"system/audit-repair":12,"kimi/moonshot-v1-8k":1,"repair":1,"fill-slots":2,"owner":1},"head":"58d57c68b8fe4cde1c3cb0c11d3d6bfa647f7e911cc9e67213c6aa2614248159"},"provenance":[{"ts":"2026-06-29T08:33:51.480Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: KPV: Gut-Specific Anti-Inflammatory\n\nGeneral evidence-graded intro for KPV: Gut-Specific Anti-Inflammatory. Data-first peptide definition article.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"kpv-gut-specific-anti-inflammatory\",\n  \"title\": \"KPV: Gut-Specific Anti-Inflammatory\",\n  \"body\": \"## Overview\\nKPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH).\\n\\n## Mechanism\\nKPV is transported into intestinal epithelial and immune cells via the PepT1 transporter (mechanistic, human cell lines). It inhibits NF-κB and MAP kinase pathways, reducing pro-inflammatory cytokine secretion without broad systemic immunosuppression (mechanistic).\\n\\n## Preclinical Evidence\\nIn two murine models of colitis (DSS- and TNBS-induced), oral KPV reduced histologic inflammation, colon shortening, and pro-inflammatory cytokine expression (preclinical, mouse studies; Kannengiesser et al. 2008; Dalmasso et al. 2008).\\n\\nNo large-scale human clinical trials for KPV exist (absence of human data; multiple sources as of 2026). A related tripeptide K(D)PT showed signals in one phase 2 UC trial, but this is distinct.\\n\\n## Repair Framing\\nKPV calms gut lining inflammation locally via epithelial uptake, distinct from systemic immune suppression (mechanistic/preclinical).\\n\\n## Limitations\\nAll proposed gut benefits derive from cell culture and rodent models; human safety, dosing, and efficacy data are absent.\",\n  \"register\": \"source_ledger\",\n  \"claims\": [\n    {\n      \"id\": \"c1\",\n      \"text\": \"KPV is transported into intestinal epithelial and immune cells via the PepT1 transporter and inhibits NF-κB and MAP kinase pathways\",\n      \"section\": \"Mechanism\",\n      \"tier\": \"mechanistic\",\n      \"source_ids\": [\"s1\"],\n      \"source_status\": \"sourced\",\n      \"why_material\": \"Core mechanism for gut-specific action\"\n    },\n    {\n      \"id\": \"c2\",\n      \"text\": \"In DSS- and TNBS-induced murine colitis models, oral KPV reduced histologic inflammation, disease activity, and cytokine expression\",\n      \"section\": \"Preclinical Evidence\",\n      \"tier\": \"preclinical\",\n      \"source_ids\": [\"s2\", \"s3\"],\n      \"source_status\": \"sourced\",\n      ","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"1e2b2eaccf4cf78d18417da174b7d3ddea6bb4a9364ae8acb1141d9dbe6dc94e"},{"ts":"2026-06-29T09:52:06.720Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1e2b2eaccf4cf78d18417da174b7d3ddea6bb4a9364ae8acb1141d9dbe6dc94e","hash":"5e2dcff29beef6d38439a7cf29a47e979b550dcde93dedc45eddc01745a75e39"},{"ts":"2026-06-29T09:52:21.203Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"8 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5e2dcff29beef6d38439a7cf29a47e979b550dcde93dedc45eddc01745a75e39","hash":"69a5849969fc6443e8490dc373fde045bb463880d6e7b2eff7486aea2fdd2e9f"},{"ts":"2026-06-29T09:52:51.473Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"9 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"69a5849969fc6443e8490dc373fde045bb463880d6e7b2eff7486aea2fdd2e9f","hash":"aa862604e8001e41efccdddca6c40b43ea59b6ed80458973c6deafa2c807991b"},{"ts":"2026-06-29T09:53:10.000Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"aa862604e8001e41efccdddca6c40b43ea59b6ed80458973c6deafa2c807991b","hash":"c4bd58cee67dbed7d733aaaf23dc4c5d59899338c96a4fbb9ff7b19a21a7e154"},{"ts":"2026-06-29T09:54:08.805Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c4bd58cee67dbed7d733aaaf23dc4c5d59899338c96a4fbb9ff7b19a21a7e154","hash":"bc7141022e4d91ef97bb64a20e3f7ac11a5780e4f00020e9741af2735a2a2b70"},{"ts":"2026-06-29T09:54:37.991Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"bc7141022e4d91ef97bb64a20e3f7ac11a5780e4f00020e9741af2735a2a2b70","hash":"76f66dc71048d011cfff49f077a5bcaafd80c85ca653cb19add85216ec3416a7"},{"ts":"2026-06-29T09:55:06.701Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"76f66dc71048d011cfff49f077a5bcaafd80c85ca653cb19add85216ec3416a7","hash":"6c1b0568d4594b4f5c00516473131e7b0ff424c5cec4432f7f04de65e17a9931"},{"ts":"2026-06-29T09:55:21.429Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6c1b0568d4594b4f5c00516473131e7b0ff424c5cec4432f7f04de65e17a9931","hash":"cd58acab8bfa9eda276be5439664245302e7618cdd4e23c6364f04fe531d586a"},{"ts":"2026-06-29T09:56:20.552Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"cd58acab8bfa9eda276be5439664245302e7618cdd4e23c6364f04fe531d586a","hash":"fe4828dbbda40eff352d4ab5b60aef71d04d8dcd60eb0c4adb419e8753f930a2"},{"ts":"2026-06-29T09:56:49.582Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fe4828dbbda40eff352d4ab5b60aef71d04d8dcd60eb0c4adb419e8753f930a2","hash":"3c8a7ef2d3298364f7fdd02fbdc97740499ea47390d84d5c1190fe5b524d41d0"},{"ts":"2026-06-29T09:57:08.782Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3c8a7ef2d3298364f7fdd02fbdc97740499ea47390d84d5c1190fe5b524d41d0","hash":"bef2dc74d0df270e535e626f3fcc99939a7c839f9edf76f85109cb86016ff2e9"},{"ts":"2026-06-29T09:57:34.943Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"bef2dc74d0df270e535e626f3fcc99939a7c839f9edf76f85109cb86016ff2e9","hash":"e5824fee819fd6eb90fe772f637c052961746d94d1c1412903477329e8ee76f1"},{"ts":"2026-06-29T09:58:09.571Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e5824fee819fd6eb90fe772f637c052961746d94d1c1412903477329e8ee76f1","hash":"d6cc7bc09050e22fd27d4ab2b9a32097b8743b11bcca4e07093da04eaa581218"},{"ts":"2026-06-29T09:58:45.610Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d6cc7bc09050e22fd27d4ab2b9a32097b8743b11bcca4e07093da04eaa581218","hash":"f9e7f35eb97f5327d7f307b37475f533e442050307fd220b0b01261a38b42add"},{"ts":"2026-06-29T12:47:26.419Z","model":"system/audit-repair","action":"repair","prompt":"","input":"kpv","response":"{\"materialized\":0,\"before\":[\"3 claims missing posted_by\",\"76 orphan sources (no claim link)\",\"missing constitution slots: what_it_is, who_claims_what, what_is_known, what_is_unknown, disclaimer\"],\"after\":[\"76 orphan sources (no claim link)\",\"missing constitution slots: what_it_is, who_claims_what, what_is_known, what_is_unknown, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f9e7f35eb97f5327d7f307b37475f533e442050307fd220b0b01261a38b42add","hash":"01808b817f2adaceef700d6811cbe009ca2a96546f77d3647c536859c8d76607"},{"ts":"2026-06-29T12:47:27.030Z","model":"system/audit-repair","action":"claim","prompt":"","input":"kpv c4","response":"KPV: Gut-Specific Anti-Inflammatory is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"01808b817f2adaceef700d6811cbe009ca2a96546f77d3647c536859c8d76607","hash":"ac9d1ee4067fe42cd560c56be8e6b564d2e5fc6bf0aab7961c949e56c9bb97af"},{"ts":"2026-06-29T12:47:27.115Z","model":"system/audit-repair","action":"claim","prompt":"","input":"kpv c5","response":"Per this ledger on KPV: Gut-Specific Anti-Inflammatory: 36 scientific and 42 anecdotal sources are catalogued; 2 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ac9d1ee4067fe42cd560c56be8e6b564d2e5fc6bf0aab7961c949e56c9bb97af","hash":"9b3cd9fdcd687f60ad6852e4dfecaf2af85be0371f11256799e2df544299890c"},{"ts":"2026-06-29T12:47:27.208Z","model":"system/audit-repair","action":"claim","prompt":"","input":"kpv c6","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9b3cd9fdcd687f60ad6852e4dfecaf2af85be0371f11256799e2df544299890c","hash":"49a42a5cbb9512c4b26e120da9b4940624165631cea542adf3c54c5723841d67"},{"ts":"2026-06-29T12:47:27.277Z","model":"system/audit-repair","action":"claim","prompt":"","input":"kpv c7","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"49a42a5cbb9512c4b26e120da9b4940624165631cea542adf3c54c5723841d67","hash":"d3b8104efb18c6ec178e89ff246b354ad0c4b408f9be68e17e2be16860a1a903"},{"ts":"2026-06-29T12:47:28.176Z","model":"system/audit-repair","action":"repair","prompt":"","input":"kpv","response":"{\"materialized\":0,\"before\":[\"76 orphan sources (no claim link)\",\"missing constitution slots: who_claims_what\"],\"after\":[\"76 orphan sources (no claim link)\",\"missing constitution slots: who_claims_what\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d3b8104efb18c6ec178e89ff246b354ad0c4b408f9be68e17e2be16860a1a903","hash":"60b3ba7015f9d6926b5483f10eb8e556cff34f90f632e6eb95a32b3bce7701ca"},{"ts":"2026-06-29T12:50:39.299Z","model":"system/audit-repair","action":"repair","prompt":"","input":"kpv","response":"{\"materialized\":76,\"before\":[\"76 orphan sources (no claim link)\",\"missing constitution slots: who_claims_what\"],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"60b3ba7015f9d6926b5483f10eb8e556cff34f90f632e6eb95a32b3bce7701ca","hash":"5f4d5c5a7cfe7f68d657a9e1383f83dcab261efdbb5956734cac8ba5723b2fe7"},{"ts":"2026-06-29T12:50:41.437Z","model":"system/audit-repair","action":"repair","prompt":"","input":"kpv","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5f4d5c5a7cfe7f68d657a9e1383f83dcab261efdbb5956734cac8ba5723b2fe7","hash":"3547ca553b8349a4a012ffa4ccdb97a06a43281e4bd44e576a072c7b09f45ad4"},{"ts":"2026-06-29T13:22:39.223Z","model":"system/audit-repair","action":"repair","prompt":"","input":"kpv","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3547ca553b8349a4a012ffa4ccdb97a06a43281e4bd44e576a072c7b09f45ad4","hash":"dfae83a3c07bad85c98afc69243c46e8cbf5b20fbc50df46fd433d0598335beb"},{"ts":"2026-06-29T13:22:40.417Z","model":"system/audit-repair","action":"repair","prompt":"","input":"kpv","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"dfae83a3c07bad85c98afc69243c46e8cbf5b20fbc50df46fd433d0598335beb","hash":"057d95f3e1faa3d196486944e20ebb8f3154e437089e1d60a582dfb87c1b5c74"},{"ts":"2026-06-29T13:51:51.177Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"kpv","response":"As Kimi, I am adding explicit gaps regarding what is unknown and naming who claims what from anecdotes where missing, as per the instructions.","tokens_in":3103,"tokens_out":376,"cost":0,"prev":"057d95f3e1faa3d196486944e20ebb8f3154e437089e1d60a582dfb87c1b5c74","hash":"249ec4175c275f1cb2f33cffdf87a11511705581191ca43f4c435ae331437ae4"},{"ts":"2026-06-29T13:53:36.769Z","model":"system/audit-repair","action":"repair","prompt":"","input":"kpv","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"249ec4175c275f1cb2f33cffdf87a11511705581191ca43f4c435ae331437ae4","hash":"5fb61d4ccd901f58f58b65b8a0ac9d945c51d3cf06f3108be83e7217c0aa2410"},{"ts":"2026-06-29T13:53:38.203Z","model":"system/audit-repair","action":"repair","prompt":"","input":"kpv","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5fb61d4ccd901f58f58b65b8a0ac9d945c51d3cf06f3108be83e7217c0aa2410","hash":"278d6ffa6ca6553c6c83da2a8bb6e5f39d3841abec5c1f1110a75a3ee1bb0a0c"},{"ts":"2026-06-29T15:36:36.049Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"278d6ffa6ca6553c6c83da2a8bb6e5f39d3841abec5c1f1110a75a3ee1bb0a0c","hash":"d7407be7bd925875d296a946bdaf03d644997ecdfc47b254f631c01004fd3217"},{"ts":"2026-06-29T15:37:04.119Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d7407be7bd925875d296a946bdaf03d644997ecdfc47b254f631c01004fd3217","hash":"faa962b56fd671b9649766802ac6e83e4cb87401cf60f3d30fd7b1dc819525a1"},{"ts":"2026-06-29T17:40:22.145Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"faa962b56fd671b9649766802ac6e83e4cb87401cf60f3d30fd7b1dc819525a1","hash":"27ad9edd4063070963777ddf19fa03697cd0407aad3933ec9d91ee06d7daff36"},{"ts":"2026-06-29T17:40:39.503Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"27ad9edd4063070963777ddf19fa03697cd0407aad3933ec9d91ee06d7daff36","hash":"81415113885747bb4063a8b3c1a4449714b33da1f239f2f30861f3f2153fc3a2"},{"ts":"2026-06-29T17:41:11.142Z","model":"grok-4.3","action":"sources","prompt":"","input":"kpv","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"81415113885747bb4063a8b3c1a4449714b33da1f239f2f30861f3f2153fc3a2","hash":"af07dfffdc2b74d7f94a6032b59157cf95385c858ce78bd6a39eb11a790a0c7c"},{"ts":"2026-06-29T19:28:01.253Z","model":"repair","action":"repair","prompt":"","input":"kpv","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":18}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"af07dfffdc2b74d7f94a6032b59157cf95385c858ce78bd6a39eb11a790a0c7c","hash":"6eba82a4d4bcb7c5e514e8610b5dc25638693e687bd32252e5df89980a76cb2b"},{"ts":"2026-06-29T20:42:04.832Z","model":"fill-slots","action":"claim","prompt":"","input":"kpv c109","response":"KPV: Gut-Specific Anti-Inflammatory is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6eba82a4d4bcb7c5e514e8610b5dc25638693e687bd32252e5df89980a76cb2b","hash":"f7d1badc7528ff587f99589ba349f5d094458ceaefc71b587fe370130ac94eef"},{"ts":"2026-06-29T20:42:07.449Z","model":"fill-slots","action":"claim","prompt":"","input":"kpv c110","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f7d1badc7528ff587f99589ba349f5d094458ceaefc71b587fe370130ac94eef","hash":"e56cd3862f16d32339fc0c2c870d03a92a54bb16837d995654542379ea77f42e"},{"ts":"2026-07-17T02:39:56.879Z","model":"owner","action":"voxel_divide","prompt":"","input":"kpv","response":"11 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e56cd3862f16d32339fc0c2c870d03a92a54bb16837d995654542379ea77f42e","hash":"58d57c68b8fe4cde1c3cb0c11d3d6bfa647f7e911cc9e67213c6aa2614248159"}]}